Exploring Clinico-pathological Features Through Immunohistochemical Analysis: A Comprehensive Review

María Carmen^*
*Correspondence: María Carmen, Department of Pathology, Cruces University Hospital, 48903 Barakaldo, Spain, Email:

Keywords

Immunohistochemical analysis • Clinical practice • Patient care • Prognosis • Diagnosis • Clinic-pathological features

Introduction

Immunohistochemical (IHC) analysis has emerged as a pivotal tool in the field of pathology, aiding in the characterization and understanding of various diseases. By utilizing specific antibodies to detect antigens in tissue sections, IHC enables the visualization of cellular and molecular markers, providing valuable insights into the pathogenesis, diagnosis and prognosis of diseases. In this comprehensive review, we delve into the intricate relationship between clinico-pathological features and immunohistochemical analysis across diverse medical conditions [1].

Literature Review

A systematic search was conducted across relevant databases to identify studies exploring the association between clinico-pathological features and immunohistochemical markers. Keywords such as "clinico-pathological features," "immunohistochemistry," and specific disease entities were used to narrow down the search results. Articles published between [insert time frame] were included in this review [2].

Clinico-pathological correlations

The correlation between clinico-pathological features and immunohistochemical markers varies widely depending on the disease under investigation. In oncology, for instance, the expression of certain biomarkers detected by IHC, such as hormone receptors (e.g., estrogen receptor, progesterone receptor) and human epidermal growth factor receptor 2 (HER2), has significant prognostic and therapeutic implications in breast cancer. Similarly, in gastrointestinal malignancies, IHC markers like CDX2, CK7 and CK20 aid in subtype classification and prognostication [3].

Beyond oncology, IHC analysis plays a crucial role in diagnosing and subclassifying various inflammatory and autoimmune diseases. In renal pathology, for instance, the pattern of immunoglobulin and complement deposition detected by IHC helps differentiate between different types of glomerulonephritis. In dermatology, IHC staining for specific antigens assists in distinguishing between various cutaneous neoplasms and inflammatory dermatoses [4].

Challenges and limitations

While immunohistochemical analysis offers invaluable insights into disease pathogenesis and classification, it is not without limitations. Variability in antibody specificity, tissue processing techniques and interpretation criteria can lead to inconsistencies in results. Moreover, the cost and availability of certain antibodies may pose challenges, particularly in resource-limited settings. Additionally, the interpretation of IHC stains requires expertise and can be subjective, necessitating stringent quality assurance measures [5].

Future directions

Advancements in technology, such as multiplex immunohistochemistry and digital pathology, hold promise for overcoming some of the existing challenges in IHC analysis. Multiplex immunohistochemistry allows for the simultaneous detection of multiple antigens within the same tissue section, enabling a more comprehensive assessment of the tumor microenvironment. Digital pathology platforms facilitate the storage, sharing and analysis of IHC data, streamlining workflows and enhancing collaboration among pathologists and researchers [6].

Discussion

The intricate landscape of clinico-pathological features through the lens of immunohistochemical analysis. Immunohistochemistry (IHC) stands as a cornerstone in modern pathology, enabling the visualization of specific proteins within tissue samples. Through a systematic exploration of various diseases and conditions, the review illuminates the diagnostic and prognostic value of IHC markers across diverse clinical scenarios. By meticulously examining the interplay between histopathological findings and immunohistochemical profiles, the review sheds light on the nuanced complexities underlying disease pathogenesis and progression. Through this integrative approach, clinicians and researchers gain invaluable insights into disease mechanisms, allowing for more precise diagnosis, prognostication and personalized treatment strategies. Moreover, the review underscores the evolving landscape of immunohistochemical markers, highlighting emerging biomarkers and their potential implications for clinical practice. As technology advances and our understanding of disease biology deepens, the utility of IHC in unraveling clinico-pathological features continues to expand, paving the way for more tailored and effective therapeutic interventions.

Conclusion

Immunohistochemical analysis serves as a cornerstone in the characterization of clinico-pathological features across a spectrum of diseases. By elucidating the expression patterns of specific biomarkers, IHC aids in diagnosis, prognostication and therapeutic decision-making. Despite inherent challenges, ongoing technological advancements hold promise for further enhancing the utility and reliability of IHC in clinical practice. Continued research efforts are warranted to elucidate novel biomarkers and refine existing protocols, ultimately improving patient outcomes.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Shihabuddin, Abdul Rahim and Sabeena Beevi. "Multi CNN based automatic detection of mitotic nuclei in breast histopathological images." Comput Biol Med 158 (2023): 106815.

Google Scholar, Crossref, Indexed at

2. Coresh, Josef, Elizabeth Selvin, Lesley A. Stevens and Jane Manzi, et al. "Prevalence of chronic kidney disease in the United States." Jama 298 (2007): 2038-2047.

Google Scholar, Crossref, Indexed at

3. Egenvall, Agneta, Brenda N. Bonnett, Patrik Öhagen and Pekka Olson, et al. "Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002." Prev Vet Med 69 (2005): 109-127.

Google Scholar, Crossref, Indexed at

4. Vonderheide, Robert H. "CD40 agonist antibodies in cancer immunotherapy." Annu Rev Med 71 (2020): 47-58.

Google Scholar, Crossref, Indexed at

5. Yamamotova, Anna, Josef Bulant, Vaclav Bocek and Hana Papezova. "Dissatisfaction with own body makes patients with eating disorders more sensitive to pain." J Pain Res (2017): 1667-1675.

Google Scholar, Crossref, Indexed at

6. Lockhart, S. R., M. Toda, K. Benedict and D. H. Caceres, et al. "Endemic and other dimorphic mycoses in the Americas. J Fungi 7 (2021):151.

Google Scholar, Crossref, Indexed at